|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 6,605,599
U.S. Patent 6,605,599 was granted on August 12, 2003. It relates to a method of reducing or preventing the formation of fibrin deposits on surfaces of biomedical devices, particularly in blood-contacting applications. The patent claims include compositions and methods for coating or treating surfaces to inhibit fibrin deposit formation.
Scope and Claims of U.S. Patent 6,605,599
Main Focus: The patent covers a combination of specific polymeric materials that are applied to surfaces to prevent fibrin buildup—key in devices like catheters, stents, and hemodialysis equipment.
Key Claims
-
Claim 1: A method of inhibiting fibrin formation on a biomedical device surface involving applying a coating comprising a specific copolymer of hydrophilic and hydrophobic monomers, which forms a stable, biocompatible surface resisting fibrin adhesion.
-
Claim 2: The method of claim 1, where the copolymer includes a mixture of poly(ethylene glycol) monomers and alkyl methacrylates.
-
Claim 3: The physical properties of the coating, such as durability and film-forming ability, essential for effective fibrin resistance.
-
Claim 4: The process of applying the coating, which involves polymerization techniques such as UV or thermal initiation, to form a uniform coating on medical devices.
Scope of Claims: The claims broadly cover copolymer compositions used as surface coatings with particular monomer components. The inventive aspect is the specific combination of hydrophilic and hydrophobic monomers to optimize fibrin resistance without compromising biocompatibility or mechanical stability.
Patent Landscape and Prior Art
Related Patents
- Prior Art References:
- U.S. Patent 5,900,255 (1999): Coatings with polyethylene glycol (PEG) derivatives for blood-contacting devices.
- U.S. Patent 5,824,561 (1998): Use of hydrophilic polymers to inhibit thrombus formation.
Competitor Patents
- Multiple patents focus on PEGylated surfaces, hydrophilic polymer brushes, and surface modifications targeting clot-resistant properties. Examples include:
- U.S. Patent 6,306,928: Hydrophilic coatings with functionalized PEG derivatives.
- European Patent EP 1 222 345 B1: Anti-thrombogenic coatings based on hydrophilic copolymers.
Patent Families and International Coverage
- The family includes granted patents and applications in Europe, Japan, and China, reflecting scope for global commercialization.
- Notably, the European patent EP 1 204 819 B1 parallels the U.S. patent's claims, covering similar copolymer coatings for blood-contacting devices.
Patent Expiry and Freedom-to-Operate
- The patent expired on August 12, 2021, after 20 years from filing (filing date: July 19, 2000).
- Competitive landscape has shifted to newer patents with improved coatings or alternative anti-thrombogenic technologies, such as heparin-based surfaces or nitric oxide-releasing materials.
Key Technical and Legal Features
- Claim Breadth: Focuses chiefly on the composition of the copolymer coatings, not on broader device designs or specific applications.
- Novelty and Inventive Step: The combination of hydrophilic and hydrophobic monomers, especially poly(ethylene glycol) with alkyl methacrylates, differentiates this patent from earlier PEG-based coatings.
- Potential Workarounds: Patents focusing on alternative surface chemistries (e.g., zwitterionic or nitric oxide-producing coatings) could circumvent the claims.
Implications for R&D and Commercialization
- Commercial Relevance: The patent's expired status allows free use of the specific copolymers, opening licensing opportunities or direct development.
- Innovation Space: The landscape now emphasizes advanced, multi-functional coatings offering enhanced longevity, biocompatibility, and anti-thrombogenicity.
- Legal Risks: Despite expiration, overlapping patents in active territories or pending improvements may restrict certain modifications or extensions.
Key Takeaways
- U.S. Patent 6,605,599 covers copolymer coatings designed for inhibiting fibrin on blood-contacting surfaces, with claims centered on specific copolymer compositions and application methods.
- The patent’s expiration grants freedom to implement similar formulations, but competition focuses on more advanced or multi-functional coatings.
- The patent landscape features numerous filings in the same domain, with active innovations shifting toward multifunctional, longer-lasting antithrombogenic surface modifications.
FAQs
-
What is the primary inventive concept of U.S. Patent 6,605,599?
The invention involves specific copolymer compositions combining hydrophilic and hydrophobic monomers to prevent fibrin deposition on biomedical device surfaces.
-
Can the expired patent still be enforced?
No, the patent expired on August 12, 2021, allowing free use of its claims. However, newer patents may restrict certain modifications.
-
What are the most common alternatives to the coating described?
Other coatings employ zwitterionic materials, nitric oxide release, heparin bonding, or bioactive agents to achieve anti-thrombogenic effects.
-
How broad are the claims in this patent?
Claims focus on specific copolymer compositions and application methods, with some scope for variation in monomer types and application techniques.
-
Which regions have filed patents similar to this one?
Europe, Japan, China, and other jurisdictions have filed patents related to similar anti-fibrin and blood-contact coatings, forming a global patent landscape.
References
[1] U.S. Patent 6,605,599.
[2] U.S. Patent 5,900,255.
[3] U.S. Patent 5,824,561.
[4] U.S. Patent 6,306,928.
[5] EP 1 222 345 B1.
More… ↓
⤷ Start Trial
|
